// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

In patients with treatment-sensitive cancers, does systemic anti-cancer therapy increase the chance of malignant pleural effusion control?

Nina Holling - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Pleural pointillism and early contrast enhancement as imaging biomarkers of pleural malignancy

Selina Tsim - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Isolated pleural thickening referred to pulmonologists - challenges and diagnosis

Philip Evans - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Mesothelioma is associated with ipsilateral thoracic muscle loss

Andrew C Kidd - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Malignant pleural mesothelioma

N/A

The UK timed diagnostic lung cancer pathway: a pleural disaster

Avinash Aujayeb - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Retrospective application of the YEARS algorithm to an ambulatory PE clinic cohort

Sameen Toor - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Cataract 6, multiple types

N/A

Late Breaking Abstract - Thromboembolic complications in COVID-19 patients admitted to two large East London hospitals

Stuart Innes - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Late Breaking Abstract - Pulmonary embolism in patients with COVID-19: Time to change thromboprophylaxis paradigm

Aarani Mahalingam - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary embolism

N/A

Intermediate High Risk (IHR PE: The value of a PE Lysis Team (PELT

Charlotte Carter - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Heparin

Efficacy of age adjusted d-dimer in excluding pulmonary embolism in patients with cancer

Ahsan Zahid - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary embolism

N/A

Does abdominal-pelvic CT detect occult malignancy in patients with unprovoked pulmonary embolism?

Bana Hawramy - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary embolism

N/A

What is the incidence of pleural effusions in acute pulmonary emboli?

Karl Jackson - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Multi-omic profiling in pulmonary arterial hypertension

Pablo Otero-Núñez - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

Tamsulosin Hydrochloride

New rare variant associations with distinct phenotypes in patients with pulmonary arterial hypertension revealed with Bayesian inference

Emilia Świetlik - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Protein truncating mutations in ATP13A3 promote pulmonary arterial hypertension

Ekaterina Legchenko - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study

Marius M. Hoeper - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Riociguat

Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH: Insights from TRITON

Olivier Sitbon - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

macitentan

REPAIR: long-term effects of macitentan on the right ventricle (RV in pulmonary arterial hypertension (PAH

David Kiely - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

macitentan

Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial

Ekkehard Grünig - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic thromboembolic pulmonary hypertension

N/A

EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multi-centre study

Robert Lewis - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Copyright © 2026. QuantiNova All rights reserved